ALDOCUMAR is indicated for the prophylaxis and/or treatment of deep venous thrombosis, pulmonary embolism or thromboembolic complications associated with atrial fibrilation and/or replacement of heart valves. ALDOCUMAR reduces the risk of death from recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization.
For treatment of deep venous thrombosis (DVT) or pulmonary embolism and deep vein thrombosis (DVT) prophylaxis or pulmonary embolism prophylaxis. For the treatment and further prevention of DVT or pulmonary embolism (PE) after the initial, acute phase of treatment.
ALDOCUMAR is indicated for the prophylaxis and/or treatment of deep venous thrombosis, pulmonary embolism or thromboembolic complications associated with atrial fibrilation and/or replacement of heart valves. ALDOCUMAR reduces the risk of death from recurrent myocardial infarction and thromboembolic events such as stroke or systemic embolization.
